Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.45 |
| ▸ | PPARD | Q03181 | 8/20 | 0.44 |
| ▸ | PPARA | Q07869 | 8/20 | 0.44 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500269 | 0.89 | FFAR1 (0.44) | FFAR1PPARDPPARAPPARGNPC1 | |
| SCHEMBL6502357 | 0.87 | FFAR1 (0.48) | FFAR1PPARDPPARAPPARGNPC1 | |
| SCHEMBL6487110 | 0.83 | PPARD (0.57) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL6495846 | 0.82 | FFAR1 (0.48) | FFAR1PPARDPPARAPPARGMAPT | |
| SCHEMBL6489153 | 0.77 | PPARD (0.53) | FFAR1PPARDPPARAPPARGALDH1A1 | |
| SCHEMBL6500025 | 0.76 | NR1H4 (0.51) | FFAR1PPARDPPARAPPARGNPC1 | |
| SCHEMBL5015433 | 0.76 | PPARD (0.57) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL6526499 | 0.76 | NPC1 (0.44) | FFAR1PPARDPPARAPPARGNPC1 | |
| SCHEMBL5657706 | 0.75 | PPARD (0.55) | FFAR1PPARDPPARAPPARGMAPT | |
| SCHEMBL6495570 | 0.74 | PPARD (0.51) | FFAR1PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203151-A1 | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions | KALYPSYS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| WO-2005060958-A1 | (5- (2-PHENYL)-THIAZOL-5-YLMETHOXY)-INDOL-1-YL) -ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE HUMAN PPAR-DELTA RECEPTOR FOR THE TREATMENT OF METABOLIC DISORDERS SUCH AS TYPE 2 DIABETES | KALYPSYS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203151-A1 | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions | PPARG, PPARD, PPARA | FFAR1 43/4885PPARD 2/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.